Kev,
If we look to NASDAQ for valuation metrics, PAB should be headed to +15 to 20c
Given the Aussie market doesn't value Biotechs the same way, an ACW style rerating makes sense.
So, $200m market cap for a Phase 1 ready asset is where I'm at...so 10c.
Then it depends on P1 news in the next 6 months...partnership / funding etc.
Yale Uni is where the IP comes from, I'm expecting US based accumulation...looks like it has already started
See how we go.
.
THIS IS HUGE!!!, page-198
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(16.7%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $1.479K | 422.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 34 | 27095209 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 27489307 | 16 |
View Market Depth
| Last trade - 10.56am 08/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |